ArticleBritish journal of clinical pharmacology2026
Evaluating the clinical efficacy of combinatorial pharmacogenomic-guided treatment in schizophrenia patients.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsThis study aims to evaluate the impact of combinatorial pharmacogenomic (CPGx)-guided treatment (CPGT) on medication patterns, symptom remission and hospital stay in patients with schizophrenia.
methodsThis retrospective study included schizophrenia patients hospitalized at Shandong Mental Health Center from 2019 to 2022 who underwent self-paid CPGx testing. Based on the temporal sequence of CPGx testing relative to hospitalization, their hospitalizations were classified into the CPGT and the treatment-as-usual (TAU) group. The χ
resultsThis study included 895 hospitalization records from 494 patients with schizophrenia, with 331 in the CPGT and 564 in the TAU. CPGT added genotype-related prescriptions such as amisulpride, aripiprazole, risperidone and clozapine in the superior genotype subgroup (P < 0.05), reduced the dosage of risperidone in the slow metabolism subgroup, and increased the doses of clozapine, risperidone, quetiapine and olanzapine in the fast metabolism subgroup (P < 0.05). Compared with TAU, CPGT was associated with a higher percentage change in PANSS score during hospitalization (β = 6.79, 95% CI: 3.26-10.33) and a higher response rate (OR = 1.62; 95% CI, 1.21-2.16). Additionally, the hospital stay in the CPGT group was reduced by 4.80 (95% CI, 1.92-7.68) days.
conclusionsOur findings demonstrate that CPGx significantly improves treatment outcomes in hospitalized patients with schizophrenia, supporting that CPGx can guide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.